Tocilizumab, a monoclonal antibody against interleukin-6 (IL-6), has emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms recently. In recent studies, clinicians have discussed the treatment response of Tocilizumab therapy in COVID-19 infected patients. The demographic, treatment, laboratory parameters of C-reactive protein (CRP) and IL-6 before and after Tocilizumab therapy and clinical outcome in COVID-19 patients were retrospectively assessed.
Tocilizumab appears to be an effective treatment option in COVID-19 patients with a risk of cytokine storms. And for critically ill patients with elevated IL-6, the repeated dose of the Tocilizumab is recommended.
Genentech, maker of another IL-6 inhibitor, Tocilizumab (Actemra), is working with the FDA to initiate a randomized, double-blind, placebo-controlled phase III clinical trial in collaboration with BARDA to evaluate the safety and efficacy of Tocilizumab plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care. The primary and secondary endpoints of the study include clinical status, mortality, mechanical ventilation, and ICU variables.
An open label, non-controlled, non–peer reviewed study was conducted in China in 21 patients with severe respiratory symptoms related to COVID-19. All had a confirmatory diagnosis of SARS-CoV-2 infection
KRISHGEN BIOSYSTEMS offers a CE marked kit for measurement of Tocilizumab (ACTEMRA) ELISA. The ELISA estimates the levels of Tocilizumab in human serum and plasma.
|Cat No||Product Particulars||Pack Size|
|KBI1022||KRIBIOLISA™ Tocilizumab (ACTEMRA) ELISA||ELISA 96 wells|
Tocilizumab treatment in COVID-19: A single center experience.
J Med Virol. 2020 Apr 6. doi: 10.1002/jmv.25801.
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J.
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia
CancerNetwork - home of the journal ONCOLOGY
by Hannah Slater, March 26, 2020
Dr Jayaraman D. Lead Scientist, leading CRO companyI have been working with a team from KRISHGEN on an assay development and customization before giving us. The project was complicated and needed technical expertise in immunology. I was very pleased with their technical competence and also mastering immunology and delivering a tough project to us on time. Their rigor, punctuality and expertise have been a recipe for the high standards, I would expect for such project from them. Kudos, Krishgen Team!!!
Mr Ramesh Sravanan, VP-Supply ChainThe expertise and command on the logistics chain including the regulatory guidelines from Krishgen is something we admire. As they often indicate, let us do the supplies, and let your team focus on science … is really something the company works on. Delivering consistently, with less than 1% error or delay consistently is the key to their success.
Dr Keith Stevens, visiting Scientist, Norfolk University, UKTo have a company understand science and work with them, is a pleasure. Krishgen not only sells but understands what it sells in terms of the complex cutting edge sceince.
Mellisa Karlowski, Lead Researcher, east coast US CROThe company is good on understanding its customers, is transparent and speaks science. This makes it easier for us to work with them.
ARE YOU A DISTRIBUTOR
Join KRISHGEN as a verified distributor to get access to over 1 million sku’s, including reagents, biochemicals and assays. Your one stop vendor for life sciences.